IL106580A - Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof - Google Patents

Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof

Info

Publication number
IL106580A
IL106580A IL106580A IL10658093A IL106580A IL 106580 A IL106580 A IL 106580A IL 106580 A IL106580 A IL 106580A IL 10658093 A IL10658093 A IL 10658093A IL 106580 A IL106580 A IL 106580A
Authority
IL
Israel
Prior art keywords
water
casein
salt
pharmaceutical composition
insoluble
Prior art date
Application number
IL106580A
Other languages
English (en)
Other versions
IL106580A0 (en
Original Assignee
Merz & Cp Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Cp Gmbh & Co filed Critical Merz & Cp Gmbh & Co
Publication of IL106580A0 publication Critical patent/IL106580A0/xx
Publication of IL106580A publication Critical patent/IL106580A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL106580A 1992-08-04 1993-08-03 Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof IL106580A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (2)

Publication Number Publication Date
IL106580A0 IL106580A0 (en) 1993-12-08
IL106580A true IL106580A (en) 1998-02-08

Family

ID=6464804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL106580A IL106580A (en) 1992-08-04 1993-08-03 Pharmaceutical composition in solid dosage forms having an extended two- stage release profile containing both water soluble and water- insoluble salts of casein and production thereof

Country Status (17)

Country Link
US (1) US5382601A (fr)
EP (1) EP0582186B1 (fr)
JP (1) JP3560244B2 (fr)
CN (1) CN1086708A (fr)
AT (1) ATE176866T1 (fr)
AU (1) AU669731B2 (fr)
CA (1) CA2141691C (fr)
DE (2) DE4225730C2 (fr)
DK (1) DK0582186T3 (fr)
ES (1) ES2128369T3 (fr)
GR (1) GR3030227T3 (fr)
IL (1) IL106580A (fr)
LT (1) LT3201B (fr)
LV (1) LV10182B (fr)
MX (1) MX9304675A (fr)
WO (1) WO1994003158A1 (fr)
ZA (1) ZA935614B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
WO1999003451A1 (fr) * 1997-07-16 1999-01-28 Antrin Research Limited Formulations pharmaceutiques pour administration par voie orale
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1852113A3 (fr) * 2000-12-07 2008-03-12 Neuromolecular Inc. Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CA2554959A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
WO2005079773A2 (fr) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Methodes et compositions destinees au traitement de l'epilepsie, des troubles epileptiques et d'autres troubles du systeme nerveux central
CA2556216A1 (fr) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Methodes et compositions de traitement de troubles psychiatriques
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR100901927B1 (ko) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
EP1765287A2 (fr) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Formulations a liberation immediate de formes de dosage oral de memantine
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
EP1827385B1 (fr) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Composition pharmaceutique contenant memantine dans une forme à liberation prolongée pour le tratiement de dementia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (fr) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition et procédé de traitement d'une maladie neurologique
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
WO2006121560A2 (fr) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Procedes et compositions pour le traitement des pathologies associees au systeme nerveux central
NZ562120A (en) * 2005-04-28 2010-07-30 Eisai R&D Man Co Ltd Composition comprising donepezil and memantine as antidementia agents
US20060270742A1 (en) * 2005-05-02 2006-11-30 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
EP1966611B1 (fr) * 2005-12-23 2012-07-25 Alk-Abelló A/S Procede d'evaluation de la dissolution de produits pharmaceutiques
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
US20080067108A1 (en) * 2006-09-14 2008-03-20 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2583669A1 (fr) 2007-10-10 2013-04-24 Rubicon Research Private Limited Comprimés de chlorhydrate de mémantine à dissolution orale et au goût masqué
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
EP2363119A1 (fr) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Nouvelle composition pharmaceutique utile pour le traitement des personnes affectées par des maladies neurodégénératives ou neurovasculaires
WO2012101653A2 (fr) 2011-01-25 2012-08-02 Cadila Healthcare Limited Compositions pharmaceutiques de mémantine à libération modifiée
US20130323309A1 (en) 2011-02-17 2013-12-05 Lupin Limited Sustained Release Composition of Memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
MX2015001917A (es) 2012-08-16 2015-10-29 Teva Pharma Composiciones farmaceuticas de memantina.
EP2954009A1 (fr) * 2013-02-08 2015-12-16 Basf Se Fabrication de matériaux composites inorganiques-organiques par séchage réactif par pulvérisation
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN117860718A (zh) 2017-08-24 2024-04-12 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU20200087A7 (es) 2020-11-24 2022-07-08 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
CH603545A5 (fr) * 1972-04-20 1978-08-31 Merz & Co
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
AU593821B2 (en) * 1985-08-06 1990-02-22 Excel Technologies International Corporation Treating agent for liquid media
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
EP0550436A1 (fr) * 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Microspheres de proteines et leurs procedes d'utilisation
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
WO1991017745A1 (fr) * 1990-05-23 1991-11-28 Southwest Research Institute Systeme a filament d'acheminement d'un medicament et procede
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

Also Published As

Publication number Publication date
ZA935614B (en) 1995-02-03
IL106580A0 (en) 1993-12-08
WO1994003158A1 (fr) 1994-02-17
LTIP839A (lt) 1994-08-25
GR3030227T3 (en) 1999-08-31
JPH07509479A (ja) 1995-10-19
LV10182A (lv) 1994-10-20
AU4706993A (en) 1994-03-03
EP0582186B1 (fr) 1999-02-24
CN1086708A (zh) 1994-05-18
JP3560244B2 (ja) 2004-09-02
LT3201B (en) 1995-03-27
AU669731B2 (en) 1996-06-20
EP0582186A1 (fr) 1994-02-09
DK0582186T3 (da) 1999-09-27
ATE176866T1 (de) 1999-03-15
US5382601A (en) 1995-01-17
CA2141691A1 (fr) 1994-02-17
DE59309388D1 (de) 1999-04-01
DE4225730C2 (de) 2003-04-30
DE4225730A1 (de) 1994-02-10
CA2141691C (fr) 2002-04-09
ES2128369T3 (es) 1999-05-16
MX9304675A (es) 1994-03-31
LV10182B (en) 1995-04-20

Similar Documents

Publication Publication Date Title
US5382601A (en) Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
EP1058538B1 (fr) Comprime a desintegration rapide
US5955107A (en) Pharmaceutical suspension tablet compositions
JP2720932B2 (ja) 経口投与用アセトアミノフエン錠剤の製造法及びアセトアミノフエン二層錠剤
AU2001255509B2 (en) Taste masking coating composition
EP0814771B1 (fr) Ameliorations concernant des compositions organiques
JP2007532620A (ja) 両親媒性デンプンを含む医薬組成物
AU2009289464B2 (en) Chewable sustained release formulations
US20060088594A1 (en) Highly compressible controlled delivery compositions of metformin
JP2007537169A (ja) ジェランガムを含む膨張可能な投与形態
JP2006520390A (ja) 徐放性錠剤の製造方法
JP2003508420A (ja) 経口投与に適した、制御された放出の経口用量
JPH0513132B2 (fr)
JP5663238B2 (ja) 内服固形製剤及びその製造方法
US4670251A (en) Microcrystalline tableting excipient derived from whey
US10722458B2 (en) Amphipathic lipid-based sustained release compositions
HU196711B (en) Process for producing long-acting, gastric acid neutralizing pharmaceutics with high acid-binding capacity and increased bioavailability
EP0475894A1 (fr) Formulations améliorées de gemfibozile
IE912041A1 (en) Gemfibrozil formulations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired